Expression of vascular endothelial growth factor-C and vascular endothelial growth factor receptor-3 in esophageal squamous cell carcinoma

被引:40
作者
Omoto, Itaru [1 ]
Matsumoto, Masataka [1 ]
Okumura, Hiroshi [1 ]
Uchikado, Yasuto [1 ]
Setoyama, Tetsuro [1 ]
Kita, Yoshiaki [1 ]
Owaki, Tetsuhiro [1 ]
Kijima, Yuko [1 ]
Shinchi, Hiroyuki [1 ]
Ishigami, Sumiya [1 ]
Ueno, Shinichi [1 ]
Natsugoe, Shoji [1 ]
机构
[1] Kagoshima Univ, Grad Sch Med, Dept Digest Surg Breast & Thyroid Surg, Kagoshima 8908520, Japan
关键词
esophageal cancer; vascular endothelial growth factor-C; microlymphatic vessel density; vascular endothelial growth factor receptor-3; LYMPHATIC VESSEL DENSITY; VEGF-C; TUMOR LYMPHANGIOGENESIS; VEGF-C/VEGFR-3; AXIS; PROSTATE-CANCER; FACTOR (VEGF)-C; METASTASIS; INVASION; D2-40; ANGIOGENESIS;
D O I
10.3892/ol.2014.1823
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lymph node metastasis is one of the most important prognostic factors in esophageal squamous cell carcinoma (ESCC). Vascular endothelial growth factor (VEGF)-C and its receptor, VEGF receptor-3 (VEGFR-3), are key in the process of lymphangiogenesis. The present study immunohistochemically examined the expression of VEGF-C, VEGFR-3 and D2-40 in 119 patients with ESCC, and microlymphatic vessel density (MLVD) was calculated based on D2-40 expression counts. Positive expression of VEGF-C was found to correlate significantly with depth of tumor invasion, lymphatic invasion and lymph node metastasis (P<0.001, P<0.0001 and P<0.0001, respectively). Patients with deeper tumor invasion showed higher positivity of VEGFR-3 expression (P<0.05), while patients with lymph node metastasis showed higher MLVD (P<0.05). When patients were divided into three groups according to the expression of VEGF-C and VEGFR-3, patients with coexpression of VEGF-C and VEGFR-3 exhibited poorer prognosis and higher MLVD. The VEGF-C/VEGFR-3 axis is important in tumor lymphangiogenesis.
引用
收藏
页码:1027 / 1032
页数:6
相关论文
共 37 条
[1]  
[Anonymous], EUR J SURG ONCOL
[2]   Lymphatic invasion using D2-40 monoclonal antibody and its relationship to lymph node micrometastasis in pN0 gastric cancer [J].
Arigami, T ;
Natsugoe, S ;
Uenosono, Y ;
Arima, H ;
Mataki, Y ;
Ehi, K ;
Yanagida, S ;
Ishigami, S ;
Hokita, S ;
Aikou, T .
BRITISH JOURNAL OF CANCER, 2005, 93 (06) :688-693
[3]   Clinical significance of vascular, endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma [J].
Arinaga, M ;
Noguchi, T ;
Takeno, S ;
Chujo, M ;
Miura, T ;
Uchida, Y .
CANCER, 2003, 97 (02) :457-464
[4]   Prognostic significance of peritumoral lymphatic vessel density and VEGF-R3 in invasive squamous cell cervical cancer [J].
Botting, Shaleen K. ;
Fouad, Hala ;
Elwell, Kyler ;
Rampy, Bill A. ;
Salama, Salama A. ;
Freeman, Daniel H. ;
Diaz-Arrastia, Concepcion R. .
TRANSLATIONAL ONCOLOGY, 2010, 3 (03) :170-175
[5]   Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis [J].
Burton, Jeremy B. ;
Priceman, Saul J. ;
Sung, James L. ;
Brakenhielm, Ebba ;
An, Dong Sung ;
Pytowski, Bronislaw ;
Alitalo, Kari ;
Wu, Lily .
CANCER RESEARCH, 2008, 68 (19) :7828-7837
[6]  
Daly JM, 2000, J AM COLL SURGEONS, V190, P562, DOI 10.1016/S1072-7515(00)00238-6
[7]   Cardiovascular failure in mouse embryos deficient in VEGF receptor-3 [J].
Dumont, DJ ;
Jussila, L ;
Taipale, J ;
Lymboussaki, A ;
Mustonen, T ;
Pajusola, K ;
Breitman, M ;
Alitalo, K .
SCIENCE, 1998, 282 (5390) :946-949
[8]   Vascular endothelial growth factor: Basic science and clinical progress [J].
Ferrara, N .
ENDOCRINE REVIEWS, 2004, 25 (04) :581-611
[9]   The biology of vascular endothelial growth factor [J].
Ferrara, N ;
DavisSmyth, T .
ENDOCRINE REVIEWS, 1997, 18 (01) :4-25
[10]   Tumor lymphangiogenesis in head and neck squamous cell carcinoma - A morphometric study with clinical correlations [J].
Franchi, A ;
Gallo, O ;
Massi, D ;
Baroni, G ;
Santucci, M .
CANCER, 2004, 101 (05) :973-978